Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial - Wikidata - awgldk - TriplyDB

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

http://www.wikidata.org/entity/Q34906164

about

My approach to the treatment of scleroderma Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis Cellular targeting in autoimmunity Pharmacology and rationale for imatinib in the treatment of scleroderma An Update on the Treatment of the Cutaneous Manifestations of Systemic Sclerosis: The Dermatologist's Point of View.Systemic sclerosis: current concepts in pathogenesis and therapeutic aspects of dermatological manifestations.Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury.Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist's point of view.Targeting the PDGF signaling pathway in the treatment of non-malignant diseases.Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study.RNA interference against platelet-derived growth factor receptor α mRNA inhibits fibroblast transdifferentiation in skin lesions of patients with systemic sclerosis.Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis.Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis.Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial Systemic sclerosis disease modification clinical trials design: quo vadis?Profibrotic TGFβ responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases.Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro.Low-dose imatinib in the treatment of severe systemic sclerosis: a case series of six Chinese patients and literature review.Systemic sclerosis--challenges for clinical practice.Involvement of PDGF in fibrosis and scleroderma: recent insights from animal models and potential therapeutic opportunities Targeted therapies for systemic sclerosis.Current frontiers in systemic sclerosis pathogenesis.Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014.Update on systemic sclerosis.Cytokines in the immunopathology of systemic sclerosis.Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies.Interstitial lung disease in systemic sclerosis: current and future treatment.Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment.Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1.Getting out of a sticky situation: targeting the myofibroblast in scleroderma Use of Patterned Collagen Coated Slides to Study Normal and Scleroderma Lung Fibroblast Migration.Shiny white patches of the arms and forehead.Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).Alteration of circulating miRNAs in SSc: miR-30b regulates the expression of PDGF receptor β.Constitutive activation of c-Abl/protein kinase C-δ/Fli1 pathway in dermal fibroblasts derived from patients with localized scleroderma.Pre-transplant risk factors for cryptogenic organizing pneumonia/bronchiolitis obliterans organizing pneumonia after hematopoietic cell transplantation.Ethnic difference may contribute to the efficacy of low-dose imatinib mesylate in systemic sclerosis.

P2860

Q24618843-BB338BEC-13F0-4840-8B39-B8AB1DDB09FE Q26773161-FDFDAF18-664A-4F8F-A5A4-27EBD17C7FE3 Q26824580-EA347492-DDA2-4CCB-8DF6-55AEE197BAD5 Q26825153-DB9C4C3A-6F37-4278-A22D-8180B15A04EE Q30465733-8F3BB85F-6CFD-4ABF-93A0-BE334CAD948C Q31125829-A12DBA19-2A70-4BC7-AF42-A0E24675D2A5 Q33603627-1456753F-B3BA-4D70-B446-96FF0296CBCE Q33907242-B1E16DC1-E65B-4363-A29A-D7CE69EFE68B Q34352802-3DA73C7C-02FE-457F-AE6F-A3E7141278A2 Q34486262-DE3F1402-86E2-434A-B665-775C2A72B31C Q34663751-01FB01CB-1D53-424F-B33D-7FCBAB579DD3 Q34677487-17DBF1EC-045D-4E7C-BCD4-569D3E80461C Q35121494-9AFDB1C8-C0D4-41C3-B781-4117CDA66D81 Q35566387-993B0DC7-430F-4EF7-B470-54D6076A3B7F Q35961706-3C2BADC3-1571-4544-B372-A1ACC7525D04 Q36067226-0A44FA38-FCBB-466D-BF85-08C907613A1D Q37245959-42DAABAE-0A97-451C-894F-E3E3F8D88A33 Q37381549-CFBC3237-DEBB-4EAC-9CCC-CBACD223ACE7 Q37386864-3BC8C7EF-F0F3-46DD-A2E1-2ED32844A81A Q38033125-D823DBE4-5CE1-47A6-80A9-0AA436633044 Q38059459-454CF987-C97C-41F0-BC42-C7BBDEEA9C25 Q38073213-B28356E8-82EB-4534-9DAA-07A84DEE8EB7 Q38097276-FBB8F6D4-320F-4E86-9047-7F534A871465 Q38364957-280EE28A-0821-4FF6-9444-16457D98E957 Q38379767-E212ACFB-92BD-4D73-8FD6-49C918552A03 Q38542317-81DA7933-2B4D-4348-AF7A-8476E2A99B3A Q38543692-3D799F13-11D9-4EE9-8ADC-7E650C546B35 Q38733768-30F80B63-D45E-4A4F-9C3A-80AC48E6F78D Q38773637-4DF27406-B08A-497E-ABA7-B5465BA3BC03 Q38936954-3E4AF884-9AA9-47D4-87BB-3ACEC7AFC629 Q40292542-DA4B9EDF-FEB0-4298-9A77-A7F66A0EFA14 Q40785888-CE5376A5-818A-4755-8346-F19C2A98CE15 Q41816319-A16925F9-AA3D-4485-BEC8-15B78B7391CA Q42090906-C42E9753-BE1F-4085-B1EF-4EFDA15ACBFC Q42581810-2B76F88B-2130-4991-B1C5-F5BFD921933C Q42698900-C8FEF2F9-B3CB-404D-81D0-C015C16A4326 Q44398088-A23017D1-C1AF-4292-BC8E-FDA2863C706E Q44878948-39D63CDC-5B6C-49E3-A3DE-5E5F9FC67B07 Q45824385-623FD0C8-198E-44E8-9985-7E8EB30E09B5 Q45842378-2487391B-AA04-4B12-8419-71DC6AC1D133

P2860

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

http://www.wikidata.org/entity/Q34906164

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Imatinib mesylate (Gleevec) in ...... arm, open-label clinical trial

@ast

Imatinib mesylate (Gleevec) in ...... arm, open-label clinical trial

@en

Imatinib mesylate (Gleevec) in ...... arm, open-label clinical trial

@nl

type

label

Imatinib mesylate (Gleevec) in ...... arm, open-label clinical trial

@ast

Imatinib mesylate (Gleevec) in ...... arm, open-label clinical trial

@en

Imatinib mesylate (Gleevec) in ...... arm, open-label clinical trial

@nl

prefLabel

Imatinib mesylate (Gleevec) in ...... arm, open-label clinical trial

@ast

Imatinib mesylate (Gleevec) in ...... arm, open-label clinical trial

@en

Imatinib mesylate (Gleevec) in ...... arm, open-label clinical trial

@nl

P1433

Q34906164-4A403B89-046E-4C18-9EF5-B162A6D8E0A2

P1476

Q34906164-8E6E28E3-2143-47B7-821F-76466D7712AB

P2093

Q34906164-61C8ED04-C68E-4B0E-BF62-EDC9CA6A8D36

Q34906164-638625C1-BF33-482E-BAA8-D5062352778C

Q34906164-8A886FA9-1CEA-4C95-9C9A-315559718C4A

Q34906164-8E8D48D7-5EAF-4D23-B5AC-24A868154490

Q34906164-B65ADEA1-AA45-4121-A6D4-88EF0EAF9347

Q34906164-BEF82447-1E60-45D7-B12F-C29D826BAFCD

Q34906164-C16ABF5C-9F01-49BF-A7CD-9168F9D24155

Q34906164-D7E8ACF0-D19B-41B6-9144-A1A22AA596C8

Q34906164-EAED0CEA-4087-46A8-B04C-D90E55D725DE

Q34906164-EFE4D7EA-1E77-493E-8B02-6E7211EDDB21

P2860

Q34906164-19AC0DF7-B88E-4E2A-A913-2ED6FA66C298

Q34906164-2465566B-E049-4312-A5ED-EF3C430A4146

Q34906164-3381ED97-16B2-4A43-B1F1-6D123873E17B

Q34906164-459ED84D-55C3-4B16-8D41-260201884E92

Q34906164-54B924F1-09C5-43F7-94ED-7AD3468D76CD

Q34906164-588BCDEE-5831-4FCD-9759-6D3D5A310E3E

Q34906164-5BB19E9C-CC08-44CF-B38C-A657036AF339

Q34906164-5D4FE9ED-57FA-4428-8988-5661F587FD51

Q34906164-675B69CC-C153-413A-85CF-9A8CD75E8799

Q34906164-6B63AFF7-5452-478D-97B7-3AD8190BD8A9

P304

Q34906164-E9EC9460-3679-421D-B4AF-429C6B0F7C5B

P31

Q34906164-DD9D56A4-687D-4630-8B2E-09C360A579DD

P356

Q34906164-085218E7-252A-4294-AC56-6AD2A732871E

P407

Q34906164-D46F6BB4-B90C-4A84-BD5B-E958995C0D5C

P433

Q34906164-53B5E33D-0908-480E-A0BE-9EBC0F118114

P478

Q34906164-8DD03DF8-921C-4512-855C-EF3B69A21314

P577

Q34906164-3FB3AEEC-F6FC-427D-8267-DCE6323EFB41

P5875

Q34906164-7830D17A-3A48-4F72-B21B-FA9635FC7F4B

P698

Q34906164-8644B18E-8A1F-4596-AA99-F82DB8AE93B8

P932

Q34906164-1AC036A4-230B-41A0-8A2A-55B1B4F087F5

P356

ARD.2010.143974

P1433

Annals of the Rheumatic Diseases

P1476

Imatinib mesylate (Gleevec) in ...... arm, open-label clinical trial

@en

P2093

Cynthia M Magro

http://www.w3.org/2001/XMLSchema#string

Horatio F Wildman

http://www.w3.org/2001/XMLSchema#string

Jamie N Mersten

http://www.w3.org/2001/XMLSchema#string

Jessica K Gordon

http://www.w3.org/2001/XMLSchema#string

Kyriakos A Kirou

http://www.w3.org/2001/XMLSchema#string

Mansi Mehta

http://www.w3.org/2001/XMLSchema#string

Mary K Crow

http://www.w3.org/2001/XMLSchema#string

Robert F Spiera

http://www.w3.org/2001/XMLSchema#string

Stacey Kloiber

http://www.w3.org/2001/XMLSchema#string

Stephen Lyman

http://www.w3.org/2001/XMLSchema#string

P2860

TGF-beta signaling and the fibrotic response

Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model

Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies.

Cyclophosphamide versus placebo in scleroderma lung disease.

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.

Congestive heart failure is a rare event in patients receiving imatinib therapy.

Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.

Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study

Systemic sclerosis: a prototypic multisystem fibrotic disorder.

P304

1003-1009

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2010.143974

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50376506

http://www.w3.org/2001/XMLSchema#string

P698

21398330

http://www.w3.org/2001/XMLSchema#string

P932

3086082

http://www.w3.org/2001/XMLSchema#string